For nearly 20 years, Selexis has been helping its partners predictably, rapidly and cost-effectively generate life-saving biologic medicines and vaccines. Its SUREtechnology Platform™ is being used by clients worldwide, resulting in more than 119 biologic drug products in clinical and commercial manufacturing. Selexis is able to generate stable and high-expressing (2–7 g/L for MAbs, >1.5g/L for bispecific antibodies, fed batch in shake flask, >10 g/L in bioreactor) research cell banks (RCBs) in as little as 14 weeks.
The Selexis SURE CHO-M Cell Line is a proprietary high-performance mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies. The growth and production properties of the Selexis SURE CHO-M Cell Line are well defined, and the feed strategy has been optimized, allowing for faster and moreefficient scale-up to bioreactors. Therapeutics that are generated using Selexis SURE CHO-M cells are in both clinical trials and three include marketed products in both oncology and inflammation CHO cells have been used in the pharmaceutical industry for over 60 years
Solutions for complex human diseases are being addressed with increasingly complex protein therapeutic modalities. These include molecules such as bispecific proteins, DARPins, triabodies and novel scaffolds decorated with peptides, enzymes or growth factors, to name a few. Many, if not most, of these proteins do not exist in nature and producing them presents a range of production and secretion challenges such as ensuring appropriate folding and subunit pairing.